Immunomedics Inc. (NASDAQ:IMMU) dropped 6.2% during mid-day trading on Tuesday . The stock traded as low as $2.81 and last traded at $2.88, with a volume of 892,756 shares traded. The stock had previously closed at $3.07.

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immunomedics in a report on Tuesday, May 24th. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “sell” rating in a report on Tuesday, May 10th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $5.00 price target on shares of Immunomedics in a report on Monday, June 6th.

The firm’s 50 day moving average price is $2.59 and its 200-day moving average price is $2.86. The stock’s market capitalization is $272.09 million.

Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.06. On average, equities research analysts anticipate that Immunomedics Inc. will post ($0.57) earnings per share for the current year.

In other Immunomedics news, CEO Cynthia L. Goldenberg sold 63,959 shares of Immunomedics stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $4.09, for a total value of $261,592.31. Following the completion of the sale, the chief executive officer now directly owns 703,029 shares in the company, valued at $2,875,388.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman David M. Goldenberg sold 353,010 shares of Immunomedics stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $3.88, for a total transaction of $1,369,678.80. Following the completion of the sale, the chairman now owns 2,602,063 shares of the company’s stock, valued at $10,096,004.44. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP bought a new position in shares of Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned about 0.90% of Immunomedics at the end of the most recent quarter.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.